光滑念珠菌血流分离株在造血干细胞移植受者体内连续获得氟胞嘧啶、唑类和卡泊芬净耐药性。
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
机构信息
EA 209-Eucaryotes Pathogènes: Transports Membranaires et Chimiorésistance, Université Paris Descartes, Paris, France.
出版信息
Antimicrob Agents Chemother. 2010 Mar;54(3):1360-2. doi: 10.1128/AAC.01138-09. Epub 2009 Dec 28.
Abstract
We describe the acquisition of flucytosine, azole, and caspofungin resistance in sequential Candida glabrata bloodstream isolates collected from a bone marrow transplant patient with clinical failure. Point mutations in C. glabrata FUR1 (CgFUR1) and CgFKS2 and overexpression of CgCDR1 and CgCDR2 were observed in resistant isolates.
摘要
我们描述了一例骨髓移植患者临床治疗失败后连续分离到的光滑念珠菌血流感染株对氟胞嘧啶、唑类和卡泊芬净耐药的情况。耐药株中观察到光滑念珠菌 FUR1（CgFUR1）和 CgFKS2 点突变，以及 CgCDR1 和 CgCDR2 的过表达。
相似文献
1
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
Antimicrob Agents Chemother. 2010 Mar;54(3):1360-2. doi: 10.1128/AAC.01138-09. Epub 2009 Dec 28.
2
Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes.
J Antimicrob Chemother. 2006 Aug;58(2):458-61. doi: 10.1093/jac/dkl237. Epub 2006 Jun 6.
3
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
4
Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study.
Clin Microbiol Infect. 2017 Sep;23(9):676.e7-676.e10. doi: 10.1016/j.cmi.2017.03.014. Epub 2017 Mar 23.
5
Azole resistance of Candida glabrata in a case of recurrent fungemia.
J Clin Microbiol. 2006 Aug;44(8):3046-7. doi: 10.1128/JCM.00526-06.
6
Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.
J Clin Microbiol. 2007 Aug;45(8):2385-91. doi: 10.1128/JCM.00381-07. Epub 2007 Jun 20.
7
Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):662-5. doi: 10.1128/AAC.02265-15. Print 2016 Jan.
8
Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00195-18. Print 2018 Jun.
9
Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Antimicrob Agents Chemother. 2005 Feb;49(2):668-79. doi: 10.1128/AAC.49.2.668-679.2005.
10
Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.
J Glob Antimicrob Resist. 2019 Jun;17:221-226. doi: 10.1016/j.jgar.2019.01.006. Epub 2019 Jan 15.
引用本文的文献
1
: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen.
Curr Fungal Infect Rep. 2012 Jun;6(3):154-164. doi: 10.1007/s12281-012-0091-0.
2
Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost.
Nat Microbiol. 2024 Nov;9(11):3025-3040. doi: 10.1038/s41564-024-01819-2. Epub 2024 Oct 8.
3
and : global priority pathogens.
Microbiol Mol Biol Rev. 2024 Jun 27;88(2):e0002123. doi: 10.1128/mmbr.00021-23. Epub 2024 Jun 4.
4
Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial isolates.
J Clin Microbiol. 2024 Feb 14;62(2):e0114023. doi: 10.1128/jcm.01140-23. Epub 2024 Jan 24.
5
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Species.
Cells. 2023 Nov 19;12(22):2655. doi: 10.3390/cells12222655.
6
Cross-feeding affects the target of resistance evolution to an antifungal drug.
PLoS Genet. 2023 Oct 19;19(10):e1011002. doi: 10.1371/journal.pgen.1011002. eCollection 2023 Oct.
7
Whole-Genome Sequence Analysis of Isolates from a Patient with Persistent Fungemia and Determination of the Molecular Mechanisms of Multidrug Resistance.
J Fungi (Basel). 2023 Apr 26;9(5):515. doi: 10.3390/jof9050515.
8
Fungemia in Hospitalized Adult Patients with Hematological Malignancies: Epidemiology and Risk Factors.
J Fungi (Basel). 2023 Mar 24;9(4):400. doi: 10.3390/jof9040400.
9
Using Bioluminescence to Image Candida glabrata Urinary Tract Infections in Mice.
Methods Mol Biol. 2023;2658:239-247. doi: 10.1007/978-1-0716-3155-3_17.
10
A Review of Studies on Species in Peninsular Malaysia.
Adv Biomed Res. 2022 Nov 28;11:98. doi: 10.4103/abr.abr_3_22. eCollection 2022.
本文引用的文献
1
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.
Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9. doi: 10.1128/AAC.00443-09. Epub 2009 Jun 22.
2
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
3
Uneven distribution of mating types among genotypes of Candida glabrata isolates from clinical samples.
Eukaryot Cell. 2009 Mar;8(3):287-95. doi: 10.1128/EC.00215-08. Epub 2009 Jan 16.
4
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
5
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
6
The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Cancer. 2008 Jun;112(11):2493-9. doi: 10.1002/cncr.23466.
7
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
8
Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.
J Clin Microbiol. 2007 Aug;45(8):2385-91. doi: 10.1128/JCM.00381-07. Epub 2007 Jun 20.
9
Resistance to echinocandin-class antifungal drugs.
Drug Resist Updat. 2007 Jun;10(3):121-30. doi: 10.1016/j.drup.2007.04.002. Epub 2007 Jun 13.
10
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
J Clin Microbiol. 2007 Jun;45(6):1735-45. doi: 10.1128/JCM.00409-07. Epub 2007 Apr 18.
Zotero 插件